EGFR and non-small cell lung carcinoma: The EGFR-TKI group showed a favourable 5-year OS of 83%, which can be attributed to a relatively longer PRS (median, 38.9 months) compared to reported PRS in the AURA3 trial after systemic therapy with platinum-pemetrexed or osimertinib for first or second generation EGFR-TKI-resistant NSCLC (median, 22.5–26.8 months) [6].